Wells Fargo’s SAB Biotherapeutics SABS Stock Holding History
Bought
Maintained
Sold
Other funds holding SABS
Wells Fargo's SABS Position: Q3 2026 in Review
Wells Fargo reduced its SAB Biotherapeutics (SABS) stake by 43% in Q3 2026, selling an estimated $69.7K and leaving 24,923 shares worth $79K. The position accounts for ﹤0.01% of the portfolio, ranked #5270.
Wells Fargo first reported a position in SABS in Q2 2022 and has held it in 10 quarters since. The position peaked at $172K in Q2 2026. 102 funds tracked by Wall St. Rank hold SABS as of Q3 2026.
- Wells Fargo held 24,923 shares of SAB Biotherapeutics worth $79K as of Q3 2026.
- Wells Fargo sold 19,160 SAB Biotherapeutics shares in Q3 2026, an estimated $69.7K.
- SAB Biotherapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q3 2026, its #5270 holding.
- Wells Fargo first reported a position in SAB Biotherapeutics in Q2 2022 and has held it in 10 quarters since.
- Wells Fargo's SAB Biotherapeutics position peaked at $172K in Q2 2026.
- 102 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2026.
Based on Wells Fargo's 13F filing for Q3 2026, filed 16 Nov 2026.